Real-time enrollment status for this refractory autoimmune diseases clinical trial
Current Status
Recruiting
Checked: September 2, 2026 at 5:20 AM UTC
| NCT Number | NCT07115745 |
| Recruiting Status | Recruiting |
| Condition | Refractory Autoimmune Diseases |
| Phase | PHASE1 |
| Target Enrollment | 125 participants |
| Active Locations | 2 sites in the US |
| Sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Last Updated on CT.gov | July 14, 2026 (Jul 14, 2026) |
As of September 2, 2026: Clinical trial NCT07115745 is currently recruiting participants. This phase1 study for refractory autoimmune diseases is actively seeking new participants at 2 locations across the United States. The study is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07115745 is actively recruiting participants as of September 2, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 2 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07115745 was last updated Jul 14, 2026 (July 14, 2026). HelloStudys verifies this status automatically.